Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection by Weinberg, Marc S & Arbuthnot, Patrick
Introduction
Chronic hepatitis B virus (HBV) infection is an epidemic 
with  approximately  387  million  chronically  infected 
carriers worldwide, and chronic infection carries a high 
risk  for  serious  complications,  such  as  cirrhosis  and 
hepatocellular  carcinoma  [1,2].  Current  treatments  for 
HBV infection include immunomodulators such as inter­
feron­α (IFN­α) and nucleoside/nucleotide analogs, which 
are  reverse  transcriptase  inhibitors,  directly  blocking 
viral  replication.  Although  nucleoside  and  nucleotide 
analogs are well tolerated, the emergence of viral resis­
tance remains a problem [3]. Currently, the nucleoside/
nucleotide analogs lamivudine (3TC), adefovir, entecovir 
and telbivudine are approved for use against HBV, with 
lamivudine  being  the  most  widely  used.  However, 
prolonged  lamivudine  monotherapy  is  often  associated 
with the emergence of viral resistance to the drug [4]. 
Although cross­resistance to other nucleoside/nucleotide 
analogs, such as entecavir, has been demonstrated, the 
preferred first line of therapy includes a combination of 
nucleoside/nucleotide analogs to limit the emergence of 
resistance (reviewed in [5]). IFN­α functions to augment 
the anti­HBV immune response and has been in wide­
spread use for many years [6,7]. Currently, unmodified 
and  polyethylene  glycol  (PEG)­conjugated  IFNs  are 
licensed for therapy of HBV [8]. However, some patients 
are poorly responsive to IFN­α therapy, and it can induce 
adverse side effects, such as hepatic injury [9]. Moreover, 
IFN­α  is  often  expensive  and  unavailable  in  resource­
poor settings.
There is a dire need for new therapies for HBV infection 
and  the  emergence  of  RNA  interference  (RNAi)­based 
technologies  is  an  exciting  new  frontier  in  antiviral 
therapeutics.  RNAi  is  a  set  of  conserved  eukaryotic 
pathways  in  which  double­stranded  RNAs  (dsRNAs) 
trigger  specific  and  powerful  gene  silencing  [10,11]. 
RNAi has an important role in regulating gene expression 
through the processing of long dsRNA precursors by the 
RNase III enzymes Drosha and Dicer into endogenous 
microRNAs  (miRNAs)  or  short  interfering  RNAs 
(siRNAs). RNA ‘guide strands’ of around 22 nucleotides 
in  length  are  each  integrated  into  an  Argonaute­
containing RNA­induced silencing complex (RISC) and 
these  target  mRNAs  for  degradation  or  translational 
suppression  [12,13].  Considerable  enthusiasm  followed 
the initial discovery of RNAi in 1998 [11] as it emerged 
that  this  pathway  could  be  exploited  for  medical 
applications.  Since  then,  RNAi  technologies  have 
developed rapidly with the aim of silencing rogue viral 
and host cell genes. This is especially the case for HBV, 
for which, so far, many studies have applied RNAi­based 
tools  to  inhibit  viral  replication  in  vivo  and  in  vitro 
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© 2010 BioMed Central Ltd[14­18].  RNAi­based  modalities  differ  from  current 
therapies  in  that  they  can  be  used  to  block  various 
different  steps  in  the  viral  life  cycle,  from  viral  RNA 
replication intermediates to viral mRNAs. Importantly, 
different RNAi activators share similar pharmacological 
properties,  allowing  multiple  RNAi­based  drugs  to  be 
used  together  in  combination  treatments.  Although 
similar  to  current  multidrug  cocktail  regimes,  RNAi 
com  binations can target exclusive regions of the virus, 
thus  avoiding  problems  associated  with  multi­drug 
sensitivities  and  toxicities.  This  makes  RNAi­based 
therapies better suited to targeting rapidly evolving viral 
sequences,  preventing  the  emergence  of  drug­resistant 
virus. Lastly, because RNAi­based drugs can be expressed 
from  introduced  genes,  they  offer  the  possibility  for  a 
sustained therapeutic response.
The HBV genome and susceptibility to RNAi-based 
therapies
The HBV genome has a relaxed circular DNA (rcDNA) 
structure  that  is  partly  double  stranded  (Figure  1a) 
[19,20].  Having  infected  a  hepatocyte,  viral  rcDNA  is 
converted to covalently closed circular DNA (cccDNA), 
which  serves  as  a  template  for  the  expression  of  viral 
genes  and  for  the  formation  of  the  replicative  inter­
mediate pregenomic RNA [19­21]. This HBV replication 
intermediate exists naturally as a minichromosome and is 
analogous to the provirus of HIV­1­infected cells. There­
fore,  cccDNA  ultimately  controls  the  production  of 
progeny  viruses.  One  of  the  principal  reasons  for  the 
poor efficacy of many antiviral treatment regimens has 
been the difficulty in eliminating episomal cccDNA from 
infected hepatocytes; it can reactivate HBV replication 
following withdrawal of treatment.
The entire viral genome is approximately 3,200 bases in 
length and is remarkably compact, encoding four open 
reading frames: core, polymerase, envelope (surface) and 
hepatitis B virus X protein (Figure 1b). All open reading 
frames partially overlap, collectively covering the entire 
genome. Viral regulatory elements, which control trans­
cription and replication, are included within the protein­
coding  sequences.  Although  HBV  replicates  using  an 
error­prone reverse transcriptase, its small, economically 
arranged genome limits sequence plasticity, making HBV 
a  good  target  for  RNAi­based  therapeutic  approaches, 
which rely on nucleic acid hybridization. Moreover, the 
virus  produces  four  transcripts,  initiated  from  four 
different promoters on the cccDNA but all terminating at 
a  single  polyadenylation  site.  Therefore,  a  single  RNAi 
modality  is  theoretically  capable  of  simultaneously 
targeting all four viral mRNAs as well as the pregenomic 
RNA template (Figure 1c).
Synthetic and expressed RNAi activators that 
target HBV
Ideally,  anti­HBV  sequences  should  be  effective  at  low 
concentration  (potent),  stable,  with  no  off­target  non­
specific silencing, have limited toxic immunostimulatory 
effects  and  be  easily  delivered  in  various  prescribed 
doses.  To  achieve  this,  both  expressed  and  synthetic 
RNAi  activators  have  been  used.  Exogenous  anti­HBV 
siRNAs are synthetic analogs of mature miRNA duplexes 
and  activate  RNAi  at  the  stage  of  guide  strand 
incorporation into RISC. Expressed RNAi activators are 
produced from exogenous genetic elements and mimic 
upstream  RNAi  intermediates  that  are  recognized  by 
Drosha and/or Dicer enzymes to produce active siRNAs. 
The  chronic  nature  of  HBV  infection  means  that  a 
Figure 1. A schematic of the hepatitis B virus genome structure, 
gene arrangement and expressed transcripts. (a) The partially 
double-stranded genome is shown associated with a viral capsid 
(gray hexagon). (b) The four viral open reading frames encoding 
the core (C), polymerase (P), surface (S) and hepatitis B virus X (HBx) 
proteins, colored to show how they partially or fully overlap each 
other. (c) Four major viral RNA species (outer arrows) are transcribed 
from the covalently closed circular DNA (cccDNA) template and 
terminate at a single polyadenylation signal. Targeting the X 
transcript of the viral genome (indicated by shaded gray region) 
ensures that a single RNAi modality inhibits all viral-produced RNAs, 
including the greater-than-genome-length pregenomic RNA.
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Page 2 of 7sustained  effect  of  anti­HBV  agents  is  essential. 
Unmodified  synthetic  miRNA  mimics  generally  have  a 
short duration of efficacy and may be unsuited to treat­
ment  of  persistent  HBV  infection.  Sustained  silencing 
with chemically modified siRNAs or expressed sequences 
may therefore be preferable.
Improving safety and specificity by chemical modification
Chemical  modification  has  been  used  to  improve 
stability, silencing specificity and efficiency of the RNAi 
activators  [22].  Inclusion  of  2’­O­methyl  RNA  and 
2’­fluoro  ribose  moieties,  use  of  locked  nucleic  acid 
siRNA derivatives and incorporation of phosphorothioate 
backbone modifications have been reported to improve 
siRNA efficacy [23­26]. Substitution of ribose with the 
six­carbon  sugar  altritol  was  also  recently  found  to 
enhance stability and efficacy of siRNAs [27], and this 
chemical modification has shown promise in preclinical 
testing  against  HBV  [28].  Off­target  effects  caused  by 
immunostimulation  and  activation  of  the  Toll­like 
receptor  proteins  TLR3,  TLR7  and  TLR8  [29,30]  by 
siRNAs are important considerations in the development 
of RNAi­based HBV therapy. Avoidance of certain ‘danger’ 
motifs (such as 5’­GUCCUUCAA­3’, 5’­UGUGU­3’ and 
GU­rich sequences), ensuring that the length of siRNAs 
does  not  exceed  approximately  27  bp,  and  various 
chemical modifications can be used to diminish immuno­
stimulation [31].
Unintended  hybridization  to  host  cellular  sequences 
may be another complicating side effect of therapeutic 
siRNAs. The seed region of any potentially therapeutic 
guide  sequence  is  likely  to  be  complementary  to  non­
targeted cellular mRNA and result in non­specific trans­
lational suppression. Interestingly, a 2’­O­methyl modifi­
cation at nucleotide 2 from the 5’ end has been found to 
attenuate this off­target silencing by siRNAs [26]. Ensur­
ing a guide strand selection bias in favor of the intended 
antisense sequence is also important to limit non­specific 
gene silencing. Weak interstrand bonding at the 5’ end of 
the intended guide [32] and incorporating a 5’­O­methyl 
group  on  the  terminal  ribose  of  the  sense  strand  [33] 
facilitate appropriate selection of guide strands by RISC. 
Collectively, these results show that chemical modifica­
tions  are  very  useful  to  improve  the  safety  profile  and 
specificity of siRNAs, which are critical for development 
of anti­HBV RNAi­based therapy.
Endoribonuclease-prepared siRNAs are alternative RNAi 
activators
Endoribonuclease­prepared siRNAs (esiRNAs) have been 
developed  as  interesting  alternative  RNAi  activators 
[34,35]. These silencing sequences are different from the 
new class of endogenous siRNAs (also termed esiRNAs) 
that  have  been  found  in  Drosophila  melanogaster  [36] 
and  oocytes  of  mice  [37]  in  that  the  formation  of 
endoribonuclease­prepared  RNAs  in  vitro  involves 
processing  of  large  dsRNA  by  recombinant  Dicer  or 
Escherichia  coli  RNase  III  to  produce  a  large  pool  of 
different  siRNAs  targeted  to  a  specific  viral  sequence. 
When used against HBV, esiRNAs inhibited viral replica­
tion in culture and in vivo [38]. An intriguing observation 
was  that  esiRNAs  were  capable  of  diminishing  the 
concentration  of  viral  cccDNA  templates.  Other 
researchers  [39,40]  report  similar  findings  and  ascribe 
them to a feedback mechanism in which knockdown of 
reverse transcription of pregenomic RNA is effected by 
inhibition of HBV surface antigen production. However, 
inhibition  of  cccDNA  production  following  RNAi­
mediated HBV gene silencing has not been a constant 
observation [41], and non­specific effects as a cause for 
this observation need to be excluded [17,42].
DNA expression cassettes for delivery of RNAi
Good  progress  has  been  made  in  developing  DNA 
expression  cassettes  that  transcribe  HBV­silencing 
sequences. Short hairpin RNA (shRNA) mimics of pre­
miRNA or primary (pri­)miRNA shuttle sequences have 
typically  been  incorporated  into  expression  cassettes. 
RNA  polymerase  III  (Pol  III)  transcription  regulatory 
elements have been used successfully but a concern has 
been  that  overproduction  of  anti­HBV  shRNAs  may 
disrupt endogenous miRNA function [43]. Studies have 
recently  shown  that  Pol  II  promoters  can  be  used  in 
highly  effective  monomeric  or  multimeric  anti­HBV 
cassettes, which include features of naturally occurring 
miRNAs  [44­46].  Research  focus  has  therefore  shifted 
towards  the  use  of  weaker  Pol  III  promoters  and  the 
development of Pol II RNAi expression cassettes capable 
of  tissue­specific  and  inducible  expression  of  RNAi 
activators [45,47]. DNA encoding anti­HBV RNAi activa­
tor sequences can be propagated conveniently in plasmids 
(pDNA), PCR amplicons and highly efficient hepatotropic 
recombinant  viral  vectors  such  as  adenoviruses  and 
adeno­associated viruses (AAVs). Although insertion of 
RNAi  cassettes  into  pDNA  is  a  routine  procedure  of 
molecular  biology,  safe  and  efficient  use  of  pDNA  is 
limited  by  plasmids’  large  size,  and  the  presence  of 
antibiotic resistance genes and immunostimulatory CpG 
motifs (reviewed in [48]). DNA minicircles, which can be 
generated  by  site­specific  recombination  of  pDNA  in 
bacterial cells, may overcome these problems. However, 
variable production efficiency and problems of contami­
na  ting  pDNA  currently  limit  their  widespread  use. 
Smaller  PCR­generated  linear  expression  cassettes, 
which  include  only  essential  components  of  the  RNAi 
expression cassettes, have been used successfully as an 
alternative  template  for  expression  of  anti­HBV  RNAi 
effecters  [49].  Propagation  of  these  sequences  is 
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stabilizing flanking hairpins [50] and phosphorothioate­
modified oligonucleotide primers is easily achieved [51]. 
Linear  DNA  traverses  nucleopores  efficiently  [52]  and 
may  therefore  improve  delivery  efficiency  of  RNAi 
expression cassettes.
Models of HBV replication
The development of any type of new therapy, including 
RNAi­based HBV therapy, typically involves a series of 
investigations  that  progresses  from  initial  testing  in 
cultured  cells  to  rigorous  analysis  in  animal  models 
before clinical trials. A difficulty with research on HBV 
has  been  the  limited  availability  of  cell  lines  that  are 
infectable with HBV, as well as the lack of a suitable small 
animal  equivalent  of  human  HBV  infection.  Surrogate 
models,  which  usually  involve  transfection  of  cells  in 
culture  or  in  vivo  with  HBV  replication­competent 
plasmids, have therefore been used. Hydrodynamic injec­
tion of mice with HBV replication­competent plasmid is 
a convenient approach to simulate infection in vivo [53]. 
However, this model has some drawbacks given that the 
procedure itself is hepatotoxic and viral replication is 
transient.  HBV  transgenic  mice  have  been  used  as  a 
more  stringent  model  and  HBV  replication  in  these 
animals  resembles  the  clinical  condition  of  chronic 
HBV  infection.  Chimeric  immunodeficient  mice  that 
are  grafted  with  human  hepatocytes  have  also  been 
used as a murine model of viral replication [54,55]. The 
livers of these mice, which are colonized with human 
hepatocytes, can be infected by HBV to enable testing 
of efficacy of antiviral agents. Larger animal models of 
HBV  infection  are  available  but  are  complicated  by 
requirements for specialized housing and ethical issues. 
Examples include the woodchuck [56], tree shrew [57] 
and chimpanzee [58].
Delivery of anti-HBV RNAi activators
As nucleic acids, synthetic and expressed RNAi activators 
are large negatively charged molecules and their delivery 
to cellular targets requires the use of vectors. Although 
progress has been made in this field, achieving safe and 
efficient transport of RNAi activators to cellular targets 
remains  the  most  significant  hurdle  that  needs  to  be 
overcome before the goal of RNAi­based HBV therapy is 
realized.  The  hepatotropism  of  HBV  requires  systemic 
administration  of  antiviral  formulations.  This  is  more 
complicated  than  topical  administration  of  antivirals, 
which can be used to counter infections such as those 
caused by respiratory syncytial virus [59]. An additional 
consideration  is  that  to  achieve  sustained  silencing  of 
chronic  HBV  infection,  repeated  administration  of 
vectors  may  be  necessary,  in  which  case  avoidance  of 
immunostimulation is important.
Viral  and  non­viral  vectors  have  both  been  used  to 
deliver anti­HBV sequences in vivo. Although a variety of 
non­viral vectors can be used for this purpose, liposome 
nucleic acid complexes (lipoplexes) have been used most 
commonly.  Lipoplexes  are  compatible  with  the  use  of 
modular  assembly  to  tailor  biological  properties  for 
specific applications. An example is the addition of galac­
tose  residues  to  non­targeting  vectors  to  enable  direct 
inter  action with the liver­specific asialoglyco  protein recep­
tor [60]. Addition of ‘stealth’ molecules such as PEG can be 
used  to  improve  vector  stability  and  facilitate  passive 
targeting  of  the  liver.  Modular  lipoplexes  were  used 
successfully to deliver anti­HBV siRNAs in the stringent 
transgenic mouse model [61]. Chemically modified anti­
HBV  siRNAs,  encapsulated  within  lipids  to  form  stable 
nucleic  acid­lipid  particles  (SNALPs),  silenced  HBV 
replication  in  mice  that  had  been  subjected  to  hydro­
dynamic  injection  with  an  HBV  replication­competent 
plasmid  [23].  Recently,  rational  design  of  cationic  lipid 
components of SNALPs has been used to improve their 
efficiency [62]. siRNA doses as low as 0.01 mg per kg body 
weight were capable of silencing an endogenous hepatic 
gene. This is potentially very useful for advancing HBV 
RNAi­based therapy; administration of low doses of the 
RNAi effecter diminishes the risk of unwanted side effects.
Among  recombinant  viral  vectors,  adenoviruses  and 
AAVs  have  been  used  to  deliver  anti­HBV  expression 
cassettes in vivo. Infection of HBV transgenic mice with 
adenoviruses [14,63] or AAVs [43,64] carrying Pol II­ or 
Pol III­driven anti­HBV shRNA cassettes inhibited viral 
replication significantly. Although adenoviruses are very 
effective hepatotropic vectors, there are concerns about 
their immunostimulatory effects after systemic adminis­
tration.  To  attenuate  immune  responses  against  the 
vector  and  also  to  improve  the  anti­HBV  effects  of 
repeated administration, PEG modification of anti­HBV 
shRNA­expressing  adenoviruses  was  used  [65].  Newer 
generation  helper­dependent  or  ‘gutless’  adenoviruses, 
which  lack  viral  protein­expressing  sequences,  have 
diminished immunostimulatory properties and can also 
achieve sustained silencing. A recent study has reported 
the use of anti­HBV helper­dependent adenoviruses [66]. 
Only  modest  silencing  was  achieved,  but  this  was 
ascribed  to  low  efficacy  of  the  selected  anti­HBV 
expression cassette. The safety and low immunogenicity 
of recombinant AAVs have generated interest in this class 
of vector for delivery of anti­HBV RNAi sequences. Anti­
HBV hepatotropic AAVs have been generated by combin­
ing the widely used AAV­2 serotype with the capsid of 
the liver­specific AAV­8 [67]. To overcome diminished 
HBV silencing efficacy caused by an immune response to 
particular  AAV  serotypes,  sequential  administration  of 
different  vectors  with  different  capsids  was  used  to 
achieve sustained HBV silencing [68].
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The  progress  made  in  the  field  of  RNAi­based  HBV 
therapy has been impressive. Research on the topic has 
gained  momentum,  which  will  no  doubt  sustain  the 
continued  progress  required  to  achieve  the  goal  of 
developing  HBV  treatment  suitable  for  clinical 
applications. Nevertheless, there are significant hurdles 
that need to be overcome. These include optimizing dose 
control, limiting off­target effects, improving delivery of 
RNAi effecters and demonstration of efficacy in suitable 
animal models before embarking on clinical evaluations. 
As  the  mechanisms  responsible  for  off­target  effects 
become better understood, so the approaches to diminish 
their  significance  have  also  advanced.  New­generation 
antiviral expression cassettes and ingenious methods of 
chemical modification of synthetic siRNAs go a long way 
to avoiding unintended effects. Although promising viral 
and non­viral vectors have been developed for delivery of 
RNAi activators to hepatocytes, improvements in safety 
and efficacy remain an important objective before their 
eventual clinical application. Eliminating HBV cccDNA 
from  infected  hepatocytes  is  also  an  important 
consideration. EsiRNAs apparently caused a decrease in 
cccDNA  in  transfected  hepatocytes  in  culture  [38­40], 
but a recent study demonstrated that shRNA­mediated 
suppression did not alter intracellular cccDNA concen­
tra  tions [41].
The  current  phase  of  developing  anti­HBV  RNAi­
based therapy is still at a preclinical stage. Most studies 
have been carried out in cultured cells and in murine 
models of the infection. Although useful, these models 
have  their  limitations.  Detailed  evaluation  in  animal 
models that simulate the human condition more closely 
is a priority, and outcomes from these studies will be 
useful  to  guide  the  development  of  clinical  trials. 
Treatment  regimens  that  use  RNAi  activators  in 
combination  with  established  licensed  drugs  will  be 
interesting  to  assess  and  may  reveal  synergy  of  drug 
combinations. Despite difficulties with efficient delivery 
and  limitation  of  off­target  effects,  and  despite  the 
limited  availability  of  suitable  animal  models  of  HBV 
infection, advances in the development of RNAi­based 
HBV therapy are likely to continue to be rapid. Already, 
many other RNAi­based therapies have been tested in 
several  early­stage  clinical  trials.  Current  indications 
are  positive  that  RNAi­based  drugs  can  be  safely 
administered  to  humans  and  can  specifically  degrade 
target  RNAs  in  vivo  [69].  Moreover,  development  of 
anti­HBV  RNAi  therapies  benefits  efforts  to  inhibit 
liver­specific therapeutic targets and specifically other 
liver  infections,  such  as  hepatitis  C  virus.  Future 
research should see existing impediments surmounted 
and  the  prospects  for  advancing  RNAi­based  therapy 
for chronic HBV infection are exciting.
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